# Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)

> **NCT01583218** · PHASE3 · COMPLETED · sponsor: **Portola Pharmaceuticals** · enrollment: 7513 (actual)

## Conditions studied

- Venous Thromboembolism (VTE)

## Interventions

- **DRUG:** Betrixaban
- **DRUG:** Enoxaparin

## Key facts

- **NCT ID:** NCT01583218
- **Lead sponsor:** Portola Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03
- **Primary completion:** 2015-12
- **Final completion:** 2016-01
- **Target enrollment:** 7513 (ACTUAL)
- **Last updated:** 2023-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01583218

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01583218, "Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT01583218. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*